Karmanos Cancer Institute honored by Michigan Cancer Consortium

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE BARBARA ANN KARMANOS CANCER INSTITUTE was honored by the Michigan Cancer Consortium with the 2014 Spirit of Collaboration Award for its Jewish Women’s Health Project; and also received an Honorable Mention for its Harley Men’s Health Event.

The Spirit of Collaboration Award is the highest honor the Michigan Cancer Consortium presents to member organizations, recognizing outstanding collaborative work that significantly moves cancer prevention and control activities forward in Michigan. The award presentation took place this month during the Michigan Cancer Consortium’s annual meeting in Lansing.

Karmanos Cancer Institute’s Jewish Women’s Health Project is a collaboration of the Council of Orthodox Rabbis, the Women’s Orthodox League, The Jewish Fund, Jewish Family Service, The Jewish Community Center of Oak Park, and Kids Kicking Cancer. The purpose of the program is to better understand and help prevent the genetic risk factor of the BRCA I and II genes among Orthodox Jews.

Genetic research documents a high prevalence of the BRCA I and II and anedomatous polyposis coli genes among Ashkenazi (i.e. European) Jewish women. Mutations in these genes place carriers at a significantly greater risk for breast, ovarian, pancreatic, colorectal, and other cancers.

The Harley Men’s Health Event is a collaborative project with Wolverine Harley Davidson that has for the past three years helped to increase awareness and access to recommended cancer screenings for an underserved population in Michigan. In the past three years, the event has reached 530 community members.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login